Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H25NO4 |
| Molecular Weight | 355.4275 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12OC3=C4C(C[C@H]5N(CC=C(C)C)CC[C@@]14[C@@]5(O)CCC2=O)=CC=C3O
InChI
InChIKey=OHKCLOQPSLQCQR-MBPVOVBZSA-N
InChI=1S/C21H25NO4/c1-12(2)6-9-22-10-8-20-17-13-3-4-14(23)18(17)26-19(20)15(24)5-7-21(20,25)16(22)11-13/h3-4,6,16,19,23,25H,5,7-11H2,1-2H3/t16-,19+,20+,21-/m1/s1
Nalmexone is an opioid partial agonist or mixed agonist-antagonist with both analgesic and narcotic antagonist properties. In preclinical models parenteral nalmexone was a moderately active antagonist and therefore might have low abuse potential. At the same time, early work in man indicated analgesic
activity in doses above 20 mg.
Approval Year
Sample Use Guides
Doses of 5 mg and 10 mg of morphine were
compared with 15 mg and 30 mg of nalmexone in the first study and with 40 mg and 60 mg of nalmexone in the second one. Each patient was given a "round" of 4 medications, a low and high dose of morphine with a low and high dose of nalmexone, to establish and compare doseeffect curves of the 2 drugs. The medications were prepared in identical ampules and administered intramuscularly under random, double-blind conditions.
Route of Administration:
Intramuscular
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C681
Created by
admin on Fri Dec 15 15:48:59 GMT 2023 , Edited by admin on Fri Dec 15 15:48:59 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
AIB278UKIG
Created by
admin on Fri Dec 15 15:48:59 GMT 2023 , Edited by admin on Fri Dec 15 15:48:59 GMT 2023
|
PRIMARY | |||
|
Nalmexone
Created by
admin on Fri Dec 15 15:48:59 GMT 2023 , Edited by admin on Fri Dec 15 15:48:59 GMT 2023
|
PRIMARY | |||
|
C83978
Created by
admin on Fri Dec 15 15:48:59 GMT 2023 , Edited by admin on Fri Dec 15 15:48:59 GMT 2023
|
PRIMARY | |||
|
SUB09140MIG
Created by
admin on Fri Dec 15 15:48:59 GMT 2023 , Edited by admin on Fri Dec 15 15:48:59 GMT 2023
|
PRIMARY | |||
|
2443
Created by
admin on Fri Dec 15 15:48:59 GMT 2023 , Edited by admin on Fri Dec 15 15:48:59 GMT 2023
|
PRIMARY | |||
|
100000084461
Created by
admin on Fri Dec 15 15:48:59 GMT 2023 , Edited by admin on Fri Dec 15 15:48:59 GMT 2023
|
PRIMARY | |||
|
C005300
Created by
admin on Fri Dec 15 15:48:59 GMT 2023 , Edited by admin on Fri Dec 15 15:48:59 GMT 2023
|
PRIMARY | |||
|
CHEMBL2111160
Created by
admin on Fri Dec 15 15:48:59 GMT 2023 , Edited by admin on Fri Dec 15 15:48:59 GMT 2023
|
PRIMARY | |||
|
16676-26-9
Created by
admin on Fri Dec 15 15:48:59 GMT 2023 , Edited by admin on Fri Dec 15 15:48:59 GMT 2023
|
PRIMARY | |||
|
5360516
Created by
admin on Fri Dec 15 15:48:59 GMT 2023 , Edited by admin on Fri Dec 15 15:48:59 GMT 2023
|
PRIMARY | |||
|
DTXSID80168172
Created by
admin on Fri Dec 15 15:48:59 GMT 2023 , Edited by admin on Fri Dec 15 15:48:59 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
